Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized open-label study of LAG525 combinations in advanced triple-negative breast cancer
2017-004865-28Phase 2Unknown
- Sponsor
- Novartis
- Start
- May 2018
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in triple-negative breast cancer (TNBC) and breast cancer comparing LAG525 + spartalizumab, LAG525 + spartalizumab + carboplatin and LAG525 + carboplatin (3 arms). Primary endpoint: Overall response rate. Status: unknown.
02
Drugs
ieramilimabspartalizumabcarboplatin
03
Conditions
triple-negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on 2017-004865-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004865-28.